Connect Biopharma Holdings Profit Margin

The latest profit margin for CNTB is -5019.73% as of June 2026. That compares with -95.22% in the prior-year period — down 5172.0% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Connect Biopharma Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CNTB's profit margin moved from -95.22% to -5019.73% — a 5172.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Connect Biopharma Holdings's valuation or profitability profile.

Against Healthcare companies, CNTB currently prints -5019.73% for profit margin, while the sector average sits near 21.34%. That is roughly 23627.9% below the sector mean. Large gaps often invite a closer look at Connect Biopharma Holdings's growth, margins, and balance sheet.

Profit Margin shows how effectively Connect Biopharma Holdings converts resources into returns. At -5019.73%, CNTB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -95.22% in the prior-year period — down 5172.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CNTB's profit margin (-5019.73%), review year-over-year change from -95.22%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.